eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion

Condition: Solid Tumors

Sponsor: Merus N.V.

Full Title
MCLA-128-CL01: A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors

Study Treatment
HER2xHER3 bispecific antibody MCLA-128

Eligibility/Info
Cohort F: Advanced or metastatic NRG1 fusion positive non-small cell lung cancer that has been treated with or is ineligible for available standard of care therapy
Cohort G: Advanced or metastatic NRG1 fusion positive pancreatic cancer that has been treated with or is ineligible for available standard of care therapy
Cohort H: Advanced or metastatic NRG1 fusion positive solid tumor that has been treated with or is ineligible for available standard of care therapy

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.